HUP0002030A2 - GluR5 receptorantagonisták alkalmazása fájdalom kezelésére - Google Patents

GluR5 receptorantagonisták alkalmazása fájdalom kezelésére

Info

Publication number
HUP0002030A2
HUP0002030A2 HU0002030A HUP0002030A HUP0002030A2 HU P0002030 A2 HUP0002030 A2 HU P0002030A2 HU 0002030 A HU0002030 A HU 0002030A HU P0002030 A HUP0002030 A HU P0002030A HU P0002030 A2 HUP0002030 A2 HU P0002030A2
Authority
HU
Hungary
Prior art keywords
treatment
pain
methyl
decahydroisoquinoline
receptorantagonists
Prior art date
Application number
HU0002030A
Other languages
English (en)
Inventor
David Bleakman
David R. Helton
Smriti Iyengar
David Lodge
Paul L. Ornstein
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0002030A2 publication Critical patent/HUP0002030A2/hu
Publication of HUP0002030A3 publication Critical patent/HUP0002030A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A szelektív GluR5 receptor-antagonisták alkalmasak a fájdalomkezelésére. A találmány tárgya eljárás a fájdalom kezelésére, melyabból áll, hogy a kezelésre szoruló emlős szervezetébe hatásosmennyiségű szelektív GluR5 receptor-antagonistát juttatnak. Atalálmány további tárgyát képezik azok az új dekahidroizokinolin-származékok, melyek szelektív GluR5 receptor-antagonista aktivitássalrendelkeznek, nevezetesen a 3S,4aR,6S,8aR-6-{[(1H-tetrazol-5-il)-metil]-oxi-metil}-1,2,3,4,4a,5,6,7,8,8a-dekahidroizokinolin-3-karbonsav és a 3S,4aR,6S,8aR-6-{[(4-karboxi)-fenil]-metil}-1,2,3,4,4a,5,6,7,8,8a- dekahidroizokinolin-3-karbonsav és gyógyászatiszempontból alkalmazható sóik. Ó
HU0002030A 1997-04-07 1998-04-06 Use of glur5 receptorantagonists for the treatment of pain HUP0002030A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (en) 1997-04-07 1998-04-06 Pharmacological agents

Publications (2)

Publication Number Publication Date
HUP0002030A2 true HUP0002030A2 (hu) 2001-04-28
HUP0002030A3 HUP0002030A3 (en) 2002-01-28

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002030A HUP0002030A3 (en) 1997-04-07 1998-04-06 Use of glur5 receptorantagonists for the treatment of pain

Country Status (17)

Country Link
US (1) US6242462B1 (hu)
EP (1) EP0980358A4 (hu)
JP (1) JP2001521505A (hu)
KR (1) KR20010006075A (hu)
CN (1) CN1259126A (hu)
AU (1) AU734657B2 (hu)
BR (1) BR9809071A (hu)
CA (1) CA2285192A1 (hu)
EA (1) EA199900912A1 (hu)
HU (1) HUP0002030A3 (hu)
ID (1) ID23013A (hu)
IL (1) IL132086A0 (hu)
NO (1) NO994850L (hu)
NZ (1) NZ337827A (hu)
PL (1) PL336068A1 (hu)
TR (1) TR199902449T2 (hu)
WO (1) WO1998045270A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146697A0 (en) 1999-07-06 2002-07-25 Lilly Co Eli SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
AU5591900A (en) * 1999-07-06 2001-01-22 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
ES2306690T3 (es) * 2001-01-05 2008-11-16 Eli Lilly And Company Antagonistas de receptores de aminoacidos excitatorios.
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
AU2002228736A1 (en) 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2002058691A1 (en) * 2001-01-23 2002-08-01 Neurosearch A/S Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds
JP2005529892A (ja) 2002-04-26 2005-10-06 イーライ・リリー・アンド・カンパニー 鎮痛剤としてのデカヒドロイソキノリン−３−カルボン酸のエステルプロドラッグ
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
WO2005030148A2 (en) * 2003-09-25 2005-04-07 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
US8603980B2 (en) 2007-01-16 2013-12-10 The Johns Hopkins University Glutamate receptor antagonists and methods of use
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor

Also Published As

Publication number Publication date
NZ337827A (en) 2000-12-22
US6242462B1 (en) 2001-06-05
PL336068A1 (en) 2000-06-05
ID23013A (id) 1999-12-30
EP0980358A4 (en) 2001-02-07
EA199900912A1 (ru) 2000-04-24
HUP0002030A3 (en) 2002-01-28
EP0980358A1 (en) 2000-02-23
CA2285192A1 (en) 1998-10-15
BR9809071A (pt) 2000-08-01
WO1998045270A1 (en) 1998-10-15
AU734657B2 (en) 2001-06-21
NO994850D0 (no) 1999-10-05
CN1259126A (zh) 2000-07-05
NO994850L (no) 1999-10-05
JP2001521505A (ja) 2001-11-06
AU6955598A (en) 1998-10-30
TR199902449T2 (xx) 2000-07-21
KR20010006075A (ko) 2001-01-15
IL132086A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
HUP0002030A2 (hu) GluR5 receptorantagonisták alkalmazása fájdalom kezelésére
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
WO1999017755A3 (en) Medicaments
DK0975602T3 (da) Imidazol- og imidazolinderivater samt anvendelse heraf
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO963064L (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
FR2845000B1 (fr) Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
IT1277904B1 (it) Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
GEP20043286B (en) Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
WO2004014307A3 (en) Gal3 antagonists for the treatment of neuropathic pain
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods